Pinpointing the Factors Affecting Clinical Trial Experiences of Glioblastoma Patients

NCT05728125 | Not Yet Recruiting

• 1 other identifier: 82966461
• Study Type: observational
• Target: 500
• Locations: 0 countries
• Sites: N/A

Brief Summary

Historically, clinical study participation has been biased toward certain demographics. However, there is a shortage of studies that delve into the underlying factors that influence patient participation, both positively and negatively. Several people will be invited to enroll in this study so that it may collect a variety of data about glioblastoma clinical trial experiences and identify barriers to participation as well as the causes of participants' failure or withdrawal. The data collected from this study will be analyzed and used to improve the experiences of future glioblastoma patients who are recruited for medical trials.

Conditions

Glioblastoma

Keywords

Glioblastoma

Outcome Measures

Primary Outcomes (2)

• Number of patients who decide to participate in a glioblastoma clinical trial

  3 months

• Rate of patients who remain in glioblastoma clinical trial to trial completion

  12 months

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Glioblastoma patients who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.

You may qualify if:

• Patient has self-identified as planning to enroll in a clinical trial
• Patient has been diagnosed with glioblastoma
• Patient is a minimum of 18 years or older

You may not qualify if:

• Patient does not understand, sign, and return consent form
• Inability to perform regular electronic reporting
• Patient is pregnant

Sponsors & Collaborators

• Power Life Sciences Inc.: lead

Related Publications (3)

• Wirsching HG, Galanis E, Weller M. Glioblastoma. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2.

  PMID: 26948367 BACKGROUND

• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013 Nov 6;310(17):1842-50. doi: 10.1001/jama.2013.280319.

  PMID: 24193082 BACKGROUND

• Luo C, Song K, Wu S, Hameed NUF, Kudulaiti N, Xu H, Qin ZY, Wu JS. The prognosis of glioblastoma: a large, multifactorial study. Br J Neurosurg. 2021 Oct;35(5):555-561. doi: 10.1080/02688697.2021.1907306. Epub 2021 Jul 8.

  PMID: 34236262 BACKGROUND

MeSH Terms

Conditions

Glioblastoma

Condition Hierarchy (Ancestors)

Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Study Officials

• Michael B Gill

  Power Life Sciences Inc.

  STUDY DIRECTOR

Central Study Contacts

Michael B Gill

CONTACT

4159004227; bask@withpower.com

Study Design

• Study Type: observational
• Observational Model: CASE CROSSOVER
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 4, 2023
• First Posted: February 14, 2023
• Study Start: March 1, 2024
• Primary Completion: March 1, 2025
• Study Completion: March 1, 2026
• Last Updated: June 12, 2023

Record last verified: 2023-06